Phase I study of olaratumab in Japanese patients with advanced solid tumors

Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-α with high affinity and blocks ligand binding. This was a single-center, dose-escalation, phase I trial of olaratumab in Japanese patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Ma, Yan, Dontabhaktuni, Aruna, Nippgen, Cornelia, Nippgen, Johannes, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317910/
https://www.ncbi.nlm.nih.gov/pubmed/24816152
http://dx.doi.org/10.1111/cas.12444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317910/
https://www.ncbi.nlm.nih.gov/pubmed/24816152
http://dx.doi.org/10.1111/cas.12444

Ejemplares similares